Prelude Therapeutics Inc recorded a cumulative net loss of $-60 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 218 other companies achieving higher income per employee. While Prelude Therapeutics Inc's total ranking has deteriorated compared to the previous quarter from 3711 to 3720.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PRLD Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-765,671	-984,785	-1,259,468	-1,414,835	-1,573,646
PRLD's Total Ranking	# 3720	# 3711	# 3580	# 3686	# 3266
Seq. Net Income Change	-	-	-	-	-

PRLD Company Profile >> Back to PRLD Efficiency Comparisons >> Compare PRLD Net Income per Employee to its Competitors

PRLD Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 219
Healthcare Sector	# 588
Overall Market	# 3720

Net Income per Employee Statistics
High	Average	Low
$ -720,620	$ -1,365,097	$ -1,664,772
(Dec 31 2020)		(Sep 30 2024)

News about Prelude Therapeutics Inc Income per employee

Prelude Therapeutics Secures $25 Million in Private Placement to Propel Precision Oncology Advancements

Prelude Therapeutics Incorporated, a leading clinical-stage precision oncology company, recently unveiled its plans for a private placement earmarked to raise an estimated $25 million in gross proceeds. This funding will play a crucial role in supporting the continued development of Prelude s highly promising SMARCA2 portfolio, in addition to bolstering its working capital and serving general corporate purposes. This announcement comes at a crucial time for Prelude, as it strives to accelerate advancements in precision oncology therapies. In light of their recent financial performance and industry rankings, this private placement represents a significant step forward for the company.
Prelude s Cumulative Losses and Rising Industry Competitiveness:
During the 12-month period ending in the third quarter of 2023, Prelude Therapeutics Inc recorded a cumulative net loss of $-32 million. While this figure may raise concerns for some, it is essential to consider the context and industry-wide challenges faced by innovative clinical-stage companies. The pursuit of breakthroughs in cancer treatment often involves significant investments in research and development, which can result in short-term financial losses. Prelude s ability to secure an impressive private placement indicates investor confidence in the long-term potential of the company and its precision oncology endeavors.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-05T15:26:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.